New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
10:00 EDTSOHU, VMW, SDRL, RBC, HITT, INVN, XOMA, SDLP, PDLI, FCS, EMC, SGEN, REGN, NGS, BERYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Berry Plastics (BERY) initiated with a Buy at Citigroup... Fairchild Semiconductor (FCS) initiated with a Positive at Susquehanna... Hittite Microwave (HITT) initiated with an Outperform at Wells Fargo... New Gold (NGD) initiated with an Outperform at Credit Suisse... PDL BioPharma (PDLI) initiated with a Neutral at Credit Suisse... Regal-Beloit (RBC) initiated with a Buy at Janney Capital... Regeneron (REGN) initiated with an Outperform at Credit Suisse... Seadrill Partners (SDLP) initiated with a Buy at Citigroup... Seadrill (SDRL) initiated with a Buy at Deutsche Bank... Seattle Genetics (SGEN) initiated with an Outperform at Credit Suisse... XOMA (XOMA) initiated with an Outperform at Credit Suisse... VMWare (VMW) initiated with a Hold at Craig-Hallum... EMC (EMC) initiated with a Hold at Craig-Hallum... InvenSense (INVN) initiated with a Buy at Maxim... Sohu.com (SOHU) initiated with an Inderweight at HSBC.
News For BERY;FCS;HITT;NGS;PDLI;RBC;REGN;SDLP;SDRL;SGEN;XOMA;VMW;EMC;INVN;SOHU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 26, 2015
11:50 EDTVMW, EMCEMC-VMware report shows board knows status quo 'not an option,' says Wells Fargo
After Re/code's Arik Hesseldahl reported that EMC's (EMC) board is "actively considering" a downstream merger proposal under which it would be acquired by VMware (VMW), Wells Fargo analyst Maynard Um said he views the most important takeaway to be that the board views maintaining the status quo as "not an option" amid the rapid shift in the industry. Um thinks an EMC buy-in of VMware, which the report contends is the preferred option of EMC CEO Joe Tucci, presents a cleaner path with less variables but says that in either case it "seems clear that something will happen," which he views as a positive.
10:57 EDTSDRLEuropean oilfield service names boosted by M&A speculation, says JPMorgan
Subscribe for More Information
09:25 EDTEMCOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Abercrombie & Fitch (ANF), down 15.1%... Express (EXPR), up 9.8%... Frontline (FRO), up 10.4%... Chico's FAS (CHS), up 9.3%. ALSO HIGHER: Oshkosh (OSK), up 11.9% after being awarded a $6.7B contract by the U.S. Army... EMC Corporation (EMC), up 5.8% after Re/code reported that the board is considering a VMware (VMW) downstream merger proposal... Google (GOOG), up 4.6% after being upgraded to Conviction Buy from Neutral at Goldman... Ford (F), up 2.4% after Bloomberg reported that the company is considering returning production of Bronco and Ranger to the U.S. NOTABLE: Cameron International (CAM), up 45.4% after announcing that it will be acquired by Schlumberger (SLB). Schlumberger is down 1.9%. LOWER: WisdomTree (WETF), down 3.6% after being downgraded to Sell from Buy at Citi... Transocean (RIG), down 3.4% after proposing to cancel Q3 and Q4 dividends.
08:23 EDTEMC, VMWEMC board 'considering' VMware downstream merger proposal, Re/code reports
Subscribe for More Information
07:01 EDTEMCNimble Storage reported another 'solid' quarter, says Summit Research
Summit Research analyst Srini Nandury called Nimble Storage's (NMBL) quarterly results "solid," highlighting the company's report of strong demand, higher deal sizes and addition of an all-time high 690 new customers. The firm, which said it expects Nimble to gain share from both EMC (EMC) and NetApp (NTAP) "in short order," reiterates its Buy rating and $40 price target on Nimble shares.
August 25, 2015
18:11 EDTSDRLTranocean tanks after proposing dividend cancellations, peers follow
Subscribe for More Information
08:35 EDTVMWExtreme Networks joins VMware NSX partner ecosystem
Subscribe for More Information
08:21 EDTREGNRegeneron has multiple catalysts, says Leerink
Subscribe for More Information
August 24, 2015
07:23 EDTREGNRegeneron should be bought on pullbacks, says RBC Capital
Subscribe for More Information
August 23, 2015
12:35 EDTREGNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
16:01 EDTEMCOptions Update; August 21, 2015
Subscribe for More Information
August 20, 2015
14:39 EDTEMC, VMWEarnings Watch: Hewlett-Packard reports ahead of company split
Subscribe for More Information
August 19, 2015
07:22 EDTSDLPCitigroup to hold a conference
Subscribe for More Information
07:04 EDTBERYBerry Plastics acquisition of AVINTIV will be positive, says Deutsche Bank
Subscribe for More Information
August 18, 2015
06:23 EDTSGENSeattle Genetics approvals already factored into forecast, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes the FDA approval for Adcetris in post-transplant consolidation Hodgkin's Lymphoma as well as the "positive surprise" of the FDA converting the accelerated approval in relapsed HL to standard approval is already factored into in his sales forecast of $220M this year for the drug. He keeps an Underweight rating on Seattle Genetics with a $30 price target.
August 17, 2015
19:00 EDTSGENOn The Fly: After Hours Movers
UP AFTER EARNINGS: Fabrinet (FN), up 5.1%. ALSO HIGHER: Esperion Therapeutics (ESPR), up 10.6% after announcing that it is on track to initiate ETC-1002 Phase 3 program by the end of 2015... Seattle Genetics (SGEN), up 3.3% after announcing FDA approval of Adcetris for HL treatment. DOWN AFTER EARNINGS: MasTec (MTZ), down 7.4%... Urban Outfitters (URBN), down 2.3%. ALSO LOWER: Sunedison (SUNE), down 1% after announcing a $500M perpetual convertible preferred stock offering.
16:14 EDTSGENSeattle Genetics announces FDA approval of Adcetris for HL treatment
Seattle Genetics announced that the U.S. Food and Drug Administration has approved ADCETRIS, brentuximab vedotin, for the treatment of patients with classical Hodgkin lymphoma, HL, at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation consolidation. The approval is based on a phase 3 clinical trial called AETHERA that was designed to compare up to 16 cycles of ADCETRIS therapy administered every three weeks following auto-HSCT to placebo. The primary endpoint was met with a significant improvement in median progression-free survival of 42.9 months for patients who received ADCETRIS versus 24.1 months for patients who received placebo, an improvement of 18.8 months. In addition, data from the AETHERA trial converted the U.S. accelerated approval of the relapsed classical HL indication to regular approval. ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma, as well as other lymphoma subtypes. This is the third indication for ADCETRIS, which was granted accelerated FDA approval in August 2011 for two other indications: (1) treatment of Hodgkin lymphoma patients who fail autologous transplant or who fail at least two prior multi-agent chemotherapy regimens and are not autologous transplant candidates, and (2) treatment of systemic ALCL patients who fail at least one prior multi-agent chemotherapy regimen. The sALCL indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
06:22 EDTSGEN, REGNPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
August 14, 2015
17:29 EDTEMCGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
09:11 EDTRBCRegal-Beloit management to meet with Buckingham
Meeting to be held in Baltimore/Philadelphia on August 18 hosted by Buckingham.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use